Eikon Therapeutics Hit with Underperform Call – TLR7/8 Struggles and Crowded PARP Field Cited

Wedbush starts coverage on Eikon Therapeutics with an Underperform rating and $7 price target, citing high risks in its cancer drug pipeline including a struggling TLR7/8 agonist and crowded PARP1 inhibitors.